Compare Stocks: IONS, BIIB, ALNY, and INSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$227.12 +1.4%	$274.35	$197.81 ▼ $495.55	$29.97B	0.3	2.24 million shs	1.45 million shs
BIIB Biogen	$210.65 +0.9%	$203.47	$131.52 ▼ $219.72	$30.86B	0.17	1.06 million shs	860,079 shs
INSM Insmed	$126.33 -4.5%	$107.29	$90.39 ▼ $212.75	$28.89B	0.81	3.23 million shs	2.48 million shs
IONS Ionis Pharmaceuticals	$55.87 -1.2%	$65.96	$41.71 ▼ $86.74	$9.39B	0.41	3.03 million shs	1.22 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.42%	+5.09%	-19.25%	-20.86%	-47.49%
BIIB Biogen	+0.85%	+2.12%	+9.74%	+9.17%	+55.80%
INSM Insmed	-4.50%	-4.69%	+14.73%	+15.75%	+2.82%
IONS Ionis Pharmaceuticals	-1.17%	+2.53%	+1.71%	-24.73%	+29.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$227.12 +1.4%	$274.35	$197.81 ▼ $495.55	$29.97B	0.3	2.24 million shs	1.45 million shs
BIIB Biogen	$210.65 +0.9%	$203.47	$131.52 ▼ $219.72	$30.86B	0.17	1.06 million shs	860,079 shs
INSM Insmed	$126.33 -4.5%	$107.29	$90.39 ▼ $212.75	$28.89B	0.81	3.23 million shs	2.48 million shs
IONS Ionis Pharmaceuticals	$55.87 -1.2%	$65.96	$41.71 ▼ $86.74	$9.39B	0.41	3.03 million shs	1.22 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.42%	+5.09%	-19.25%	-20.86%	-47.49%
BIIB Biogen	+0.85%	+2.12%	+9.74%	+9.17%	+55.80%
INSM Insmed	-4.50%	-4.69%	+14.73%	+15.75%	+2.82%
IONS Ionis Pharmaceuticals	-1.17%	+2.53%	+1.71%	-24.73%	+29.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.92	Moderate Buy	$396.72	74.67% Upside
BIIB Biogen	2.58	Moderate Buy	$227.07	7.80% Upside
INSM Insmed	3.00	Buy	$205.52	62.69% Upside
IONS Ionis Pharmaceuticals	2.77	Moderate Buy	$94.65	69.41% Upside

Current Analyst Ratings Breakdown

Latest IONS, BIIB, ALNY, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	BIIB Biogen	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$300.00
8/12/2026	BIIB Biogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/10/2026	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$185.00 ➝ $195.00
8/10/2026	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/10/2026	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$179.00 ➝ $175.00
8/7/2026	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$218.00
8/7/2026	INSM Insmed	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$170.00
8/7/2026	INSM Insmed	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$207.00 ➝ $205.00
8/7/2026	INSM Insmed	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$172.00
8/7/2026	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$161.00 ➝ $169.00
8/6/2026	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$175.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$4.80B	6.33	$2.84 per share	80.09	$10.12 per share	22.44
BIIB Biogen	$10.03B	3.10	$22.82 per share	9.23	$127.56 per share	1.65
INSM Insmed	$606.42M	45.49	N/A	N/A	$3.47 per share	36.41
IONS Ionis Pharmaceuticals	$944M	9.84	N/A	N/A	$2.65 per share	21.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	42.22	23.54	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	37.28	12.85	6.45	8.32%	11.18%	6.88%	10/29/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	48.40	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	N/A

Latest IONS, BIIB, ALNY, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
INSM Insmed	0.74	3.72	3.40
IONS Ionis Pharmaceuticals	3.07	7.89	7.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
INSM Insmed	N/A
IONS Ionis Pharmaceuticals	93.86%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
INSM Insmed	2.10%
IONS Ionis Pharmaceuticals	1.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable

IONS, BIIB, ALNY, and INSM Headlines

Recent News About These Companies

Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Handelsbanken Fonder AB

August 12 at 5:51 AM | marketbeat.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 11 at 3:29 AM | americanbankingnews.com

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

August 8, 2026 | businesswire.com

Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Dimensional Fund Advisors LP

August 7, 2026 | marketbeat.com

HC Wainwright Has Negative Outlook for IONS Q3 Earnings

August 7, 2026 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

August 6, 2026 | prnewswire.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Rating of "Moderate Buy" by Analysts

August 6, 2026 | marketbeat.com

HC Wainwright Analysts Decrease Earnings Estimates for IONS

August 6, 2026 | americanbankingnews.com

HC Wainwright Issues Pessimistic Forecast for IONS Earnings

August 5, 2026 | marketbeat.com

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

August 5, 2026 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

August 4, 2026 | globenewswire.com

HC Wainwright Issues Negative Forecast for IONS Earnings

August 4, 2026 | marketbeat.com

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

August 3, 2026 | fool.com

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock

August 3, 2026 | marketbeat.com

Carmignac Gestion Invests $3.98 Million in Ionis Pharmaceuticals, Inc. $IONS

August 3, 2026 | marketbeat.com

Ionis Pharmaceuticals, Inc. $IONS Stock Position Boosted by California State Teachers Retirement System

August 3, 2026 | marketbeat.com

Perceptive Advisors LLC Makes New $37.84 Million Investment in Ionis Pharmaceuticals, Inc. $IONS

August 2, 2026 | marketbeat.com

Ionis Pharmaceuticals (NASDAQ:IONS) Director Purchases $258,000.00 in Stock

August 1, 2026 | insidertrades.com

Groupama Asset Managment Purchases 57,651 Shares of Ionis Pharmaceuticals, Inc. $IONS

August 1, 2026 | marketbeat.com

Edgestream Partners L.P. Takes $5.13 Million Position in Ionis Pharmaceuticals, Inc. $IONS

August 1, 2026 | marketbeat.com

Empowered Funds LLC Has $7.75 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS

August 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IONS, BIIB, ALNY, and INSM Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$227.12 +3.17 (+1.42%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$226.90 -0.22 (-0.10%)

As of 06:13 AM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$210.65 +1.78 (+0.85%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$210.60 -0.05 (-0.02%)

As of 06:30 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insmed NASDAQ:INSM

$126.33 -5.95 (-4.50%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$126.50 +0.17 (+0.13%)

As of 06:26 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Ionis Pharmaceuticals NASDAQ:IONS

$55.87 -0.66 (-1.17%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$55.87 +0.00 (+0.00%)

As of 04:01 AM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, BIIB, ALNY, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, BIIB, ALNY, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, BIIB, ALNY, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, BIIB, ALNY, and INSM Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Insmed NASDAQ:INSM

Ionis Pharmaceuticals NASDAQ:IONS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, BIIB, ALNY, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, BIIB, ALNY, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, BIIB, ALNY, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, BIIB, ALNY, and INSM Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Insmed NASDAQ:INSM

Ionis Pharmaceuticals NASDAQ:IONS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools